MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Karyopharm Therapeutics Inc

Chiusa

SettoreSettore sanitario

6.53 4.65

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

6.04

Massimo

6.59

Metriche Chiave

By Trading Economics

Entrata

4.1M

-33M

Vendite

6.1M

44M

EPS

-3.82

Margine di Profitto

-75.213

Dipendenti

279

EBITDA

1.8M

-23M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+135.29% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

13M

116M

Apertura precedente

1.88

Chiusura precedente

6.53

Notizie sul Sentiment di mercato

By Acuity

50%

50%

177 / 360 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Karyopharm Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 gen 2026, 21:55 UTC

Utili

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 gen 2026, 23:52 UTC

Utili

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 gen 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 gen 2026, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 gen 2026, 23:40 UTC

Discorsi di Mercato

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 gen 2026, 23:30 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 gen 2026, 23:30 UTC

Discorsi di Mercato

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 gen 2026, 22:37 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 gen 2026, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

22 gen 2026, 21:44 UTC

Utili

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 gen 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 gen 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 gen 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 gen 2026, 21:30 UTC

Utili

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Capital One To Acquire Brex >COF

22 gen 2026, 21:13 UTC

Utili

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 gen 2026, 21:11 UTC

Utili

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 gen 2026, 21:11 UTC

Utili

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 gen 2026, 21:10 UTC

Utili

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 gen 2026, 21:06 UTC

Utili

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Rev $15.58B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q EPS $3.26 >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net Interest Margin 8.26% >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net $2.13B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Adj EPS $3.86 >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net Charge-Offs $3.8B >COF

22 gen 2026, 21:05 UTC

Utili

Intuitive Surgical 4Q EPS $2.21 >ISRG

Confronto tra pari

Modifica del prezzo

Karyopharm Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

135.29% in crescita

Previsioni per 12 mesi

Media 14 USD  135.29%

Alto 19 USD

Basso 10 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Karyopharm Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

4

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.9501 / 7.66Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

177 / 360 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

help-icon Live chat